Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...
Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.